Enrique Bernal1, Jose M Gómez2, Inma Jarrín3, Alfredo Cano2, Angeles Muñoz2, Antonia Alcaraz2, Arkaitz Imaz4, Jose A Iribarren5, María Rivero6, Piedad Arazo7, Félix Gutiérrez8. 1. Department of Clinical Medicine, Universidad Católica San Antonio de Murcia and Hospital General Universitario Reina Sofía, Spain. 2. Hospital General Universitario Reina Sofía, Unidad de Enfermedades Infecciosas y Universidad de Murcia, Spain. 3. Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. 4. Hospital de Bellvitge, Barcelona, Spain. 5. Hospital de Donostia, San Sebastian, Spain. 6. Hospital de Navarra, Navarra, Spain. 7. Hospital Miguel Servet, Zaragoza, Spain. 8. Hospital General Universitario de Elche and Miguel Hernández University, Elche, Spain.
Abstract
BACKGROUND: The objective of this study was to investigate the long-term impact of low-level viremia (LLV) on all-cause mortality, AIDS and non-AIDS events (NAEs), and virological failure in patients receiving antiretroviral therapy (ART). METHODS: We analyzed ART-naive adults from the cohort of the Spanish AIDS Research Network (CoRIS) who initiated ART from 2004 to 2015 and achieved plasma viral load (VL) below 50 copies per milliliter. LLV50-199 was defined as 2 consecutive VL between 50 and 199 copies per milliliter, and LLV200-499 as 2 consecutive VL between 50 and 499 copies per milliliter with at least one between 200 and 499 copies per milliliter. Multivariable Cox models were used to estimate the association of LLV with AIDS events/death, non-AIDS events, and virological failure. RESULTS: Of 5986 patients included, 237 (4.0%) experienced LLV50-199 and 168 (2.8%) developed LLV200-499. One hundred seventy-one patients died or developed an AIDS event, 245 had any serious NAE and 280 had virological failure. LLV200-499 was strongly associated with a higher risk of both AIDS events/death [adjusted hazard ratio (aHR), 2.89; 95% confidence interval (CI), 1.41 to 5.92] and virological failure (aHR, 3.25; 95% CI: 1.77 to 5.99), whereas no differences were observed between LLV50-199 and no LLV neither for AIDS events/death (aHR, 1.84; 95% CI: 0.89 to 3.82) nor virological failure (aHR, 1.42; 95% CI: 0.78 to 2.58). LLV was not associated with the occurrence of any serious NAE. CONCLUSIONS: In this cohort, LLV200-499 was strongly associated with AIDS events/death and virological failure, but not with any serious NAE. Therefore, vigorous treatment should be implemented in patients with more than 200 copies per milliliter.
BACKGROUND: The objective of this study was to investigate the long-term impact of low-level viremia (LLV) on all-cause mortality, AIDS and non-AIDS events (NAEs), and virological failure in patients receiving antiretroviral therapy (ART). METHODS: We analyzed ART-naive adults from the cohort of the Spanish AIDS Research Network (CoRIS) who initiated ART from 2004 to 2015 and achieved plasma viral load (VL) below 50 copies per milliliter. LLV50-199 was defined as 2 consecutive VL between 50 and 199 copies per milliliter, and LLV200-499 as 2 consecutive VL between 50 and 499 copies per milliliter with at least one between 200 and 499 copies per milliliter. Multivariable Cox models were used to estimate the association of LLV with AIDS events/death, non-AIDS events, and virological failure. RESULTS: Of 5986 patients included, 237 (4.0%) experienced LLV50-199 and 168 (2.8%) developed LLV200-499. One hundred seventy-one patients died or developed an AIDS event, 245 had any serious NAE and 280 had virological failure. LLV200-499 was strongly associated with a higher risk of both AIDS events/death [adjusted hazard ratio (aHR), 2.89; 95% confidence interval (CI), 1.41 to 5.92] and virological failure (aHR, 3.25; 95% CI: 1.77 to 5.99), whereas no differences were observed between LLV50-199 and no LLV neither for AIDS events/death (aHR, 1.84; 95% CI: 0.89 to 3.82) nor virological failure (aHR, 1.42; 95% CI: 0.78 to 2.58). LLV was not associated with the occurrence of any serious NAE. CONCLUSIONS: In this cohort, LLV200-499 was strongly associated with AIDS events/death and virological failure, but not with any serious NAE. Therefore, vigorous treatment should be implemented in patients with more than 200 copies per milliliter.
Authors: Rimke Bijker; Sasisopin Kiertiburanakul; Nagalingeswaran Kumarasamy; Sanjay Pujari; Ly P Sun; Oon T Ng; Man P Lee; Jun Y Choi; Kinh V Nguyen; Yu J Chan; Tuti P Merati; Do D Cuong; Jeremy Ross; Awachana Jiamsakul Journal: Antivir Ther Date: 2020
Authors: Ryan R Cook; Jennifer A Fulcher; Nicole H Tobin; Fan Li; David Lee; Marjan Javanbakht; Ron Brookmeyer; Steve Shoptaw; Robert Bolan; Grace M Aldrovandi; Pamina M Gorbach Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Jennifer A Fulcher; Marjan Javanbakht; Chelsea L Shover; Amy Ragsdale; Ron Brookmeyer; Steven Shoptaw; Pamina M Gorbach Journal: Drug Alcohol Depend Date: 2021-02-16 Impact factor: 4.492
Authors: Olof Elvstam; Gaetano Marrone; Patrik Medstrand; Carl Johan Treutiger; Anders Sönnerborg; Magnus Gisslén; Per Björkman Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Pamela M Murnane; James Ayieko; Eric Vittinghoff; Monica Gandhi; Chaplain Katumbi; Beteniko Milala; Catherine Nakaye; Peter Kanda; Dhayendre Moodley; Mandisa E Nyati; Amy J Loftis; Mary G Fowler; Pat Flynn; Judith S Currier; Craig R Cohen Journal: J Acquir Immune Defic Syndr Date: 2021-12-15 Impact factor: 3.771
Authors: Hanna Brattgård; Per Björkman; Piotr Nowak; Carl Johan Treutiger; Magnus Gisslén; Olof Elvstam Journal: PLoS One Date: 2022-05-17 Impact factor: 3.240
Authors: V Carnimeo; I A Pulido Tarquino; S Fuentes; D Vaz; L Molfino; N Tamayo Antabak; R M Cuco; A Couto; S Lobo; J de Amaral Fidelis; J S Mulassua; I Ciglenecki; T Ellman; B Schramm Journal: JAC Antimicrob Resist Date: 2021-05-12
Authors: Aaloke Mody; Ingrid Eshun-Wilson; Kombatende Sikombe; Sheree R Schwartz; Laura K Beres; Sandra Simbeza; Njekwa Mukamba; Paul Somwe; Carolyn Bolton-Moore; Nancy Padian; Charles B Holmes; Izukanji Sikazwe; Elvin H Geng Journal: PLoS Med Date: 2019-10-29 Impact factor: 11.069